A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer - COMRADE Trial
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Enrollment
- 31
- Locations
- 1
- Primary Endpoint
- Number of participants recruited who complete the intervention
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The proposed study will assess the feasibility of an exercise and dietary intervention in men with castrate resistant prostate cancer with secondary outcomes assessing improvements in physical functioning, fatigue, quality of life, and body composition.The study will have 2 arms, with one set of participants randomized to resistance exercise training intervention plus dietary advice and the other arm will be standard of care plus exercise advice.
Detailed Description
Although there have been advances in recent years, therapeutic options remain limited for men with castrate resistant prostate cancer (CRPC). There is an unmet clinical need for interventions which can improve quality of life, functional capacity and cancer related fatigue. Adjunctive exercise therapy could be a potentially effective treatment for these men. A growing body of evidence has demonstrated numerous benefits in physiological and psychosocial outcomes in men with advanced prostate cancer. Further, there is observational evidence linking physical activity with reduced disease specific mortality after a diagnosis of cancer. Observational data also indicates that preserving skeletal muscle mass can improve responses to chemotherapy. The proposed study will assess the feasibility of an exercise and dietary intervention in men with castrate resistant prostate cancer with secondary outcomes assessing improvements in physical functioning, fatigue, quality of life, and body composition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men with Castrate resistant prostate cancer
- •Men with histologically confirmed PCa on long-term ADT with either
- •PSA\>2ng/ml above nadir or PSA level that has risen serially on at least two occasions (each at least 4 weeks apart) in the presence of castrate levels of testosterone or;
- •Evidence of symptomatic disease progression whilst undergoing first line androgen deprivation therapy (ADT) in the presence of castrate levels of testosterone or;
- •Radiographic disease progression whilst undergoing first line ADT in the presence of castrate levels of testosterone
Exclusion Criteria
- •• Participation in other trials which might bias the evaluation of the primary objectives of the present study.
- •Current participation in regular physical activity (defined as purposeful physical activity of a moderate intensity for 90 minutes per week for at least six months).
- •Unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers.
- •Uncontrolled painful or unstable bony metastatic lesions.
- •Within two months of invasive surgical treatment (transurethral surgery allowed).
- •Any physical, neurological or psychiatric impairment or disease or other condition that would limit the ability to understand and complete the study assessments and complete the required questionnaires, recall and record of dietary information would be excluded.
Outcomes
Primary Outcomes
Number of participants recruited who complete the intervention
Time Frame: 16 Weeks
Secondary Outcomes
- Number of participants who show improvement in the Physical function assessments(16 weeks)
- number of participants who adhere to the Diet diaries(16 weeks)
- number of participants who show improvement from treatment as shown by a DEXA scan(16 weeks)
- number of participants who show an increase in Muscle hypertrophy following intervention assessment(16 weeks)
- number of participants who show increases in Muscle Strength following intervention assessment(16 weeks)
- number of participants who show a higher score on Quality of life assessments following intervention(16 weeks)